KLRK1 and neoplasm: A recent study aimed at increasing NK cell activity against cancer cells utilized antibodies against the proteolytic shedding domains of MICA and MICB (the tumor ligands for NKG2D), which are often shed by the TME to inhibit NK cell function (178).